AWM
CTXR icon

Avior Wealth Management’s Citius Pharmaceuticals CTXR Stock Holding History

Avior Wealth Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$16 – 2606
2024
Q1 		$16 Buy
+1
New +$18 ﹤0.01% 3720

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avior Wealth Management's CTXR Position: Q2 2024 in Review

Avior Wealth Management sold out of Citius Pharmaceuticals (CTXR) in Q2 2024, closing a stake of 1 share — an estimated $16 sold.

Avior Wealth Management first reported a position in CTXR in Q1 2024 and held it in 1 quarter. The position peaked at $16 in Q1 2024. 72 funds tracked by Wall St. Rank hold CTXR as of Q2 2024.

  • Avior Wealth Management reported no remaining Citius Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 1 Citius Pharmaceuticals share in Q2 2024, an estimated $16.
  • Avior Wealth Management first reported a position in Citius Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Citius Pharmaceuticals position peaked at $16 in Q1 2024.
  • 72 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.